FRNM earnings analysis
10-Q · Filed November 12, 2026 · Our reading of the company's report
The latest report
Freenome delivered a strong Q3, with reported revenue of $183.489 million and EPS of $1.10, while FDA approval of SimpleScreen CRC and the October 2026 launch of SimpleScreen Lung marked meaningful commercialization…
Read full summary
Freenome delivered a strong Q3, with reported revenue of $183.489 million and EPS of $1.10, while FDA approval of SimpleScreen CRC and the October 2026 launch of SimpleScreen Lung marked meaningful commercialization progress. Liquidity appears supportive, with approximately $295.5 million of financing proceeds plus a $100.0 million milestone payment expected to fund operations into 2028. However, the company remains loss-making, with a $72.5 million nine-month net loss and $1.4 billion accumulated deficit, and future performance depends on partner milestones, conditional payer coverage and uncertain LDT regulation.
Reported figures
- Earnings per share
- $1.1
What stood out
-
Substantial Q3 revenue and EPS beat
Q3 revenue was $183.489 million and diluted EPS was $1.10, materially above the provided consensus estimates of $84.853 million and $(0.20), respectively. The filing text does not provide comparable prior-year or prior-quarter income-statement figures.
-
CRC approval and Lung launch advance pipeline
The company received FDA approval for SimpleScreen CRC v1 in July 2026 and launched SimpleScreen Lung as a laboratory-developed test in October 2026. SimpleScreen CRC is commercialized in the U.S. through Abbott under the Exact collaboration.
-
Liquidity runway extends into 2028
Management states that existing cash, cash equivalents and short-term marketable securities, including approximately $295.5 million of net proceeds from the Business Combination and PIPE Financing and a $100.0 million regulatory milestone payment, are expected to fund operations into 2028.
-
Roche platform delivery creates receivable
The company recorded an $8.0 million receivable from Roche Sequencing upon delivery of the SBX Platform on September 29, 2026, due within 30 days.
-
Disclosure controls assessed effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of September 30, 2026, and reported no material changes in internal control over financial reporting during the quarter.
What to watch
-
Large losses and accumulated deficit
The company reported net losses of $72.5 million for the nine months ended September 30, 2026 and an accumulated deficit of $1.4 billion. Management also expects significant expenses and operating losses to continue as commercialization, R&D and public-company costs increase.
-
Milestone and partner revenue concentration
The $100.0 million regulatory milestone payment received from Exact in September 2026 was a one-time payment. Future collaboration payments may depend on additional milestones, while the company also recorded only an $8.0 million Roche receivable due within 30 days, highlighting dependence on partner arrangements and milestone timing.
-
Medicare coverage remains conditional
Medicare coverage for SimpleScreen CRC under NCD 210.3 requires FDA authorization and either sensitivity of at least 90% with specificity of at least 87%, or sensitivity of at least 79% with specificity of at least 90%. Failure to satisfy the NCD or a future revision could delay, limit or eliminate coverage.
-
Potential reimbursement pressure from PAMA
PAMA-related Medicare payment reductions of up to 15% per year may resume beginning in 2027 and continue through 2029. Lower payment rates could pressure revenue, margins and commercial viability.
-
LDT regulatory uncertainty
SimpleScreen Lung was launched as an LDT but has not been reviewed, cleared or approved by the FDA. The filing states that the post-LDT-rule regulatory environment remains uncertain and that additional FDA requirements could delay or stop commercialization.
-
Convertible-note dilution and funding risk
Exact converted $50.472 million of principal and accrued interest into 3,364,814 common shares at $15.00 per share during the quarter. Additional equity or convertible financing could dilute existing holders and may carry restrictive terms.
Management's outlook
The filing text provided does not include quantitative MD&A guidance. The accompanying November 10, 2026 earnings release provided 2026 revenue guidance of $192 million to $194 million, with no prior outlook disclosed for comparison.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every FRNM trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.